No resistant mutations were found in any of the 3 groups of patients by week 96. Conclusions: (1) At week 96, besifovir 90 mg or 150 mg daily, had comparable antiviral activity with entecavir 0.5 mg daily. (2) Low serum L-carnitine levels, though occurring in a significant proportion of patients, were normalized in all patients with carnitine supplement. (3) Other than lowering of serum L-carnitine levels, no besifovir-related serious or significant adverse events were not reported. NS: Not significant Disclosures: Man-Fung Yuen – Advisory Committees

or Review Panels: GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer; http://www.selleckchem.com/products/avelestat-azd9668.html Grant/Research Support: Roche, Bristol-Myers Squibb, GlaxoSmithKline, Venetoclax mouse Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Science, Roche, Bristol-Myers Squibb, GlaxoSmithKline,

Gilead Science Jiyoon Lee – Employment: LG Life Sciences, Ltd Jeong-Ae Kim – Employment: LG Life Sciences, Ltd. Ching-Lung Lai – Advisory Committees or Review Panels: Bristol-Myers Squibb, Gilead Sciences Inc; Consulting: Bristol-Myers Squibb, Gilead Sciences, Inc; Speaking and Teaching: Bristol-Myers Squibb, Gilead Sciences, Inc this website The following people have nothing to disclose: Sang Hoon Ahn, Kwan Sik Lee, Soon Ho Um, Mong Cho, Seung Kew Yoon, Jin-Woo Lee, Neung Hwa Park, Young Oh Kweon, Joo Hyun Sohn, Kwang-Hyub Han Background The prevalence of Chronic hepatitis B virus(HBV) infection

is high in China, where most of HBV infection are due to mother to child transmission (MTCT). It has been documented that high viral load (HBV DNA>1 06IU/ml) is one of the major reasons of failure in preventing MTCT and the risk of MTCT can be reduced by antiviral therapy. However, it is not clear how to choose therapeutic strategies after childbirth for pregnant HBV carriers receiving nucleoside analogs for prevention of mother-to-child transmission (PMTCT). Objectives We aimed to investigate the outcome of Peg IFN a-2a plus adefovir after childbirth in pregnant HBV carriers who received telbivudine for PMTCT. Methods Forty-four HBeAg-positive highly viremic(HBV DNA≧6loglOIU/ml) pregnant HBV carriers (with normal ALT) were treated with telbivudine from 24th to 28th week of gestation to prevent HBV perinatal transmission between 2010 and 2011. Biochemical, serological and virological parameters were measured after 1-2 month(s) of childbirth. If a patient had 2 or more of the following 3 conditions, including ALT>80U/L, titer decrease of HBeAg >80% and reduction of HBV DNA>3 logIU/ml compared with baseline values, telbivudine would be stopped and switched to Peg IFN a-2a plus adefovir.